Testavec Limited (10844271) is a private limited with share capital incorporated on 30/06/2017 (8 years old) and registered in maidenhead, SL68BD. The company operates under SIC code 74909 and is classified as Micro.
Testavec is accelerating the fight against cancer and a range of rare genetic diseases using the world’s first human cell based in vitro platform with which to test the safety of viral vectors used to deliver gene therapy. the testavec in-vitro platform provides for primary culture, viral infection ...
Capital Statement Capital Company With Date Currency Figure
Category:Capital
Date:20-01-2026
Legacy
Category:Insolvency
Date:14-01-2026
Capital Allotment Shares
Category:Capital
Date:07-01-2026
Termination Director Company With Name Termination Date
Category:Officers
Date:29-12-2025
Confirmation Statement With Updates
Category:Confirmation Statement
Date:31-07-2025
Accounts With Accounts Type Total Exemption Full
Category:Accounts
Date:29-04-2025
Capital Allotment Shares
Category:Capital
Date:08-11-2024
Appoint Person Director Company With Name Date
Category:Officers
Date:25-07-2024
Confirmation Statement With No Updates
Category:Confirmation Statement
Date:25-07-2024
Accounts With Accounts Type Total Exemption Full
Category:Accounts
Date:26-04-2024
Confirmation Statement With Updates
Category:Confirmation Statement
Date:28-07-2023
Accounts With Accounts Type Total Exemption Full
Category:Accounts
Date:25-04-2023
Capital Return Purchase Own Shares
Category:Capital
Date:09-09-2022
Confirmation Statement With Updates
Category:Confirmation Statement
Date:26-07-2022
Change Registered Office Address Company With Date Old Address New Address
Category:Address
Date:13-05-2022
Accounts With Accounts Type Total Exemption Full
Category:Accounts
Date:19-04-2022
Resolution
Category:Resolution
Date:07-04-2022
Resolution
Category:Resolution
Date:07-04-2022
Capital Name Of Class Of Shares
Category:Capital
Date:06-04-2022
Capital Variation Of Rights Attached To Shares
Category:Capital
Date:04-04-2022
Notification Of A Person With Significant Control
Category:Persons With Significant Control
Date:08-09-2021
Notification Of A Person With Significant Control
Category:Persons With Significant Control
Date:08-09-2021
Termination Director Company With Name Termination Date
Category:Officers
Date:08-09-2021
Confirmation Statement With No Updates
Category:Confirmation Statement
Date:19-07-2021
Accounts With Accounts Type Dormant
Category:Accounts
Date:13-04-2021
Appoint Person Director Company With Name Date
Category:Officers
Date:30-11-2020
Confirmation Statement With Updates
Category:Confirmation Statement
Date:20-08-2020
Termination Director Company With Name Termination Date
Category:Officers
Date:27-07-2020
Capital Allotment Shares
Category:Capital
Date:15-04-2020
Capital Alter Shares Subdivision
Category:Capital
Date:15-04-2020
Accounts With Accounts Type Dormant
Category:Accounts
Date:24-03-2020
Appoint Person Director Company With Name Date
Category:Officers
Date:14-01-2020
Appoint Person Director Company With Name Date
Category:Officers
Date:17-12-2019
Confirmation Statement With Updates
Category:Confirmation Statement
Date:28-05-2019
Accounts With Accounts Type Dormant
Category:Accounts
Date:17-12-2018
Confirmation Statement With Updates
Category:Confirmation Statement
Date:12-07-2018
Appoint Person Director Company With Name Date
Category:Officers
Date:11-06-2018
Termination Director Company With Name Termination Date
Category:Officers
Date:10-05-2018
Accounts With Accounts Type Dormant
Category:Accounts
Date:13-02-2018
Capital Allotment Shares
Category:Capital
Date:09-01-2018
Capital Alter Shares Subdivision
Category:Capital
Date:09-01-2018
Resolution
Category:Resolution
Date:05-01-2018
Change Registered Office Address Company With Date Old Address New Address
Category:Address
Date:19-07-2017
Change Account Reference Date Company Current Shortened
Category:Accounts
Date:19-07-2017
Incorporation Company
Category:Incorporation
Date:30-06-2017
Innovate Grants
1
This company received a grant of £102588.0 for Establishment Of A Human Ips Cell Based Cardiac Gene Therapv Safety Model. The project started on 01/01/2018 and ended on 31/12/2018.